• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Sublingual immunotherapy: An important breakthrough for allergic veterinary patients

September 1, 2015

Patient safety just one of many benefits, dermatologist says.

In all the excitement of new dermatology drugs both recently released and soon to be available, Thomas Lewis II, DVM, DACVD, doesn't want veterinarians to miss out on what he considers one of the top breakthroughs in the treatment of atopic dermatitis in the last few years: the use of sublingual immunotherapy.

The injectable form of immunotherapy, of course, has been available for decades, and any practitioner who's treated an allergic dog using this protocol is familiar with its pros and cons.

Dr. Thomas Lewis“My own dog was on injectable immunotherapy for several years,” Lewis told dvm360 recently. “The injections worked, but he hated his shots. My wife hated holding him, and I hated giving them. Sublingual is a form that avoids the needles. And for many pet owners and many allergic dogs, that's a welcome change.”

And the benefits extend beyond decreased pain and increased ease of administration, says Lewis, who practices at Dermatology for Animals in Gilbert, Arizona. “There are some patients who have failed injectable immunotherapy who have a positive response to sublingual immunotherapy,” Lewis says.

Advertisement

The response can occur more quickly, as well. Rather than waiting for months to see a response to injectable immunotherapy, veterinarians often see improvement to sublingual administration in 30 days or less. “I have had patients respond to their sublingual drops within the first one and two weeks,” Lewis says.

Another feature Lewis highlights is safety. Patients who have had an adverse reaction to injectable immunotherapy usually tolerate the sublingual form much more readily. “Even patients who've had anaphylactic reactions have done just fine when we switched them over to sublingual,” he says.

Plus, the human literature shows one human fatality for every 6.4 million immunotherapy injections, but “there has never been a fatality to sublingual, according to last review I read,” Lewis says.

Of course, the limitations of sublingual immunotherapy remain the same as those associated with injectable immunotherapy. First and foremost is the challenge of correlating test results with the patient's exposure patterns. “We'll see crazy things in allergens if the clinician is not really supervising that process,” Lewis says. “It makes no sense to have a patient who is itchy year-round yet we only find a couple of tree pollens in their extract. So correlating those test results with the patient's pattern is of the utmost importance.”

Related Content:

MedicalDermatology
3 Must-reads for National Poison Prevention Week
3 Must-reads for National Poison Prevention Week
UC Davis study on eye diseases in kittens
UC Davis study on eye diseases in kittens
Dr Natalie Marks to lecture on diabetes management with Dr Adam Christman
Dr Natalie Marks to lecture on diabetes management with Dr Adam Christman

Advertisement

Latest News

AAHA Con heads to San Diego

VHMA announces latest class of CVPMs

Jaguar undergoes anesthesia to determine cause of appetite loss

New online course for veterinary business at UC Davis

View More Latest News
Advertisement